The name of the company takes its roots from the Latin Valeo artis - the art of creating health. This is precisely the mission of our company - to ensure patients' access to pharmaceutical care, which is one of the main components of the accessibility of healthcare.

Limited Liability Company "VALARTIN PHARMA" is a modern Ukrainian pharmaceutical company engaged in the development, production and promotion of competitive medicines, active pharmaceutical ingredients, dietary supplements and medical products.

The Company is the owner of a license for the production of medicines No. AE637438, issued on 04/29/2015 by the State Service of Ukraine for Medicines.

The enterprise operates a pharmaceutical quality system, developed in accordance with national and international standards in the field of medicines and dietary supplements, which ensures compliance with the requirements of Good Manufacturing Practice (GMP), Good Storage and Distribution Practices (GSP and GDP), as well as the requirements of relevant ISO standards.

The company's production facilities are certified for compliance with GMP requirements, the Regulation of the European Parliament and of the Council (EU) on the hygiene of food products, and the composition of the finished product is certified for compliance with GDP requirements.

Additionally, an environmental management system has been developed, implemented and operates in accordance with the ISO14001:2015 standard, environmental aspects and risks have been identified, which are monitored constantly.

The company's staff consists of over 155 qualified employees.

The Company aims to ensure sustainable development of the enterprise, in accordance with the approved long-term business strategy, taking into account adaptation to the conditions of martial law and the related security, economic and humanitarian crises. In particular, the Company's management will focus its efforts on ensuring the institutional stability of the enterprise, ensuring its stable operations, and implementing an innovation strategy aimed at expanding the product portfolio, investing in research and development, and capital investments in expanding production capacities and acquiring fixed assets.